Loading…
Reported covered position: Deputy Office Director, OSORA CMS Special Assistant, COO, CMS
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030.
Discussions regarding H.Con.Res. 11, FY2021 Budget Resolution
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain
Source: Senate LDA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan Discussions regarding Zero co-payment for biosimilars Discussions regarding Biogen's Healthy Climate, Healthy Lives initiative Issues related to the CHANGE Act Vial size wastage issue
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain
Discussions regarding H.R.133, the Consolidated Appropriations Act of 2021
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
Discussions regarding pharmaceutical issues related to supply chain Kingdom of Saudi Arabia issue related to pharmaceuticals H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Discussions regarding pharmaceutical issues related to supply chain Kingdom of Saudi Arabia issue related to pharmaceuticals H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding pharmaceutical issues related to supply chain Kingdom of Saudi Arabia issue related to pharmaceuticals H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Public Health Emergency Pass-Through Payment Fairness Act of 2020
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. Scientific and Medical Innovation (no bill) - Issues related to product failure and economic implications to Biogen and Innovation in general 8. S.1416 - Affordable Prescriptions for Patients Act of 2019 (entire bill) with particular emphasis on Section 2 : Product Hoping and Patent Thickening
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. S.2543 - Prescription Drug Pricing Reduction Act of 2019
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. S.2543 - Prescription Drug Pricing Reduction Act of 2019
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. Scientific and Medical Innovation (no bill) - Issues related to product failure and economic implications to Biogen and Innovation in general 8. S.1416 - Affordable Prescriptions for Patients Act of 2019 (entire bill) with particular emphasis on Section 2 : Product Hoping and Patent Thickening
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
Strengthening Health Care and Lowering Prescription Drug Costs Act
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. S.2543 - Prescription Drug Pricing Reduction Act of 2019
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. Scientific and Medical Innovation (no bill) - Issues related to product failure and economic implications to Biogen and Innovation in general 8. S.1416 - Affordable Prescriptions for Patients Act of 2019 (entire bill) with particular emphasis on Section 2 : Product Hoping and Patent Thickening
S.1416 - Affordable Prescriptions for Patients Act of 2019 pertaining to the U.S. Patent system and well as patent law as it pertains to the IP system/process.SEC. 106. RESTORATION OF PATENTS AS PROPERTY RIGHTS. Entire Bill with particular emphasis on Secti 2, product hoping and patent thickening
S.1416 - Affordable Prescriptions for Patients Act of 2019 pertaining to the U.S. Patent system and well as patent law as it pertains to the IP system/process.SEC. 106. RESTORATION OF PATENTS AS PROPERTY RIGHTS. Entire Bill with particular emphasis on Secti 2, product hoping and patent thickening
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. Scientific and Medical Innovation (no bill) - Issues related to product failure and economic implications to Biogen and Innovation in general 8. S.1416 - Affordable Prescriptions for Patients Act of 2019 (entire bill) with particular emphasis on Section 2 : Product Hoping and Patent Thickening
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. S.2543 - Prescription Drug Pricing Reduction Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan Discussions regarding Zero co-payment for biosimilars Discussions regarding Biogen's Healthy Climate, Healthy Lives initiative Issues related to the CHANGE Act Vial size wastage issue
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
Discussions regarding H.Con.Res. 11, FY2021 Budget Resolution
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding H.R.133, the Consolidated Appropriations Act of 2021
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Discussions regarding Medicaid 340B drug discount program
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Discussions regarding pharmaceutical issues related to supply chain Kingdom of Saudi Arabia issue related to pharmaceuticals H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. S.2543 - Prescription Drug Pricing Reduction Act of 2019
S.1416 - Affordable Prescriptions for Patients Act of 2019 pertaining to the U.S. Patent system and well as patent law as it pertains to the IP system/process.SEC. 106. RESTORATION OF PATENTS AS PROPERTY RIGHTS. Entire Bill with particular emphasis on Secti 2, product hoping and patent thickening
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. Scientific and Medical Innovation (no bill) - Issues related to product failure and economic implications to Biogen and Innovation in general 8. S.1416 - Affordable Prescriptions for Patients Act of 2019 (entire bill) with particular emphasis on Section 2 : Product Hoping and Patent Thickening
Changes in the Medicare Part B reimbursement system; International Pricing Index proposal; and Administration and Congressional proposal to address rebates in the Medicare Part D program.
Issues pertaining to the U.S. Patent system; Inter Partes Review process at the PTO; Patent law as it pertains to the IP system/process.
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to changes in the Medicare Part B reimbursement system; issues related to changes in Iternational Pricing Index proposal; and Administration and Congressional proposal to address rebates in the Medicare Part D program the Prescription Drug Pricing Reduction Act (PDPRA) of 2019 andH.R. 3, Lower Drug Costs Now Act of 2019).
IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
Corporate tax requirements and jobs: Domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs including the net cost of Biogen R & D and well as percentage of revenue spent on R &D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
Issues related to changes in the Medicare Part B reimbursement system; issues related to changes in Iternational Pricing Index proposal; and Administration and Congressional proposal to address rebates in the Medicare Part D program the Prescription Drug Pricing Reduction Act (PDPRA) of 2019 andH.R. 3, Lower Drug Costs Now Act of 2019).
Corporate tax requirements and jobs: Domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs including the net cost of Biogen R & D and well as percentage of revenue spent on R &D.
S.1416 - Affordable Prescriptions for Patients Act of 2019 pertaining to the U.S. Patent system and well as patent law as it pertains to the IP system/process.SEC. 106. RESTORATION OF PATENTS AS PROPERTY RIGHTS. Entire Bill with particular emphasis on Secti 2, product hoping and patent thickening
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
Domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE